4Halter F,Tarnawski AS,Schmassmann A,et al.Cyclooxygenase-2 implications on maintenance of gastric mucosal interty and ulcer healing:controversial issues and perspective[J].Gut,2010,49(3):443-445.
1[1]Robert W.Mcmurray,Kenneth J.Hardy.Cox-2 inhibitors:today and tomorrow[J].Am J Med Sci 2002,323(4):181-189.
2[2]Bombardier C,Laine L,Reicin A,etal.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis:VIGOR Study Group[J].N Engl J Med 2000,343(21):1520-1528.
3[3]Silverstein FE,Faich G,Goldstein JL,et al.Gastrointestinal toxicity with celecoxib vs NSAIDs for osteoarthritis and rheumatoid arthritis:the CLASS study:a randomized controlled trial:Celecoxib Long-term Arthritis Safety Study[J].JAMA 2000,284(10):1247-1255.
4[5]Laurence G.Howes,Henry Krum.Selective Cyclooxygenase-2 inhibitors and myocardial infarction[J].Drug safety,2002,25(12):829-835.
5[6]Matthew R.,Rhoda S.S.,Alise R.,Selective COX-2 inhibition and cardiovascular effects:a review of the rofecoxib development program[J].Am.Heart J.2003,146:591-604.
6[8]D.Craig Brater.Renal effects of cyclooxygyenase-2-selective inhibitors[J].J Pain Symptom Manage.2002,23:S15-20.
7[9]Suzanne.K,Swan,David W.Rudy.Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet[J].ANN intern Med.2000,133:1-9.
8[10]Syed R.Ahmad,Cindy Kortepeter,Allen Brinker,Renal failure associated with the use of celecoxib and rofecoxib[J].Drug safety.2002,25(7):537-544.
9[11]CPMP.Overall summary of the scientific evaluation of medicinal products containing celecoxib,etoricoxib,parecoxib,rofecoxib and valdecoxib[S].
10[12]James M.Wright.The double-edged sword of COX-2 selective NSAIDs[J].CMAJ 2002,167(10):1131-1137.
